SCHEMBL6386607

SCHEMBL6386607

Cc1c(Cl)cccc1NC1=NC(=O)C(CC(=O)N(C)c2ccccc2)S1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
USP2 O75604 1/20 0.41
MT-CO2 P00403 1/20 0.41
LMNA P02545 1/20 0.41
TTR P02766 1/20 0.41
PLA2G1B P04054 1/20 0.41
CYP1A2 P05177 1/20 0.41
PGR P06401 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
AR P10275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1605897 0.85 MAPT (0.46) MAPTCYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL6389749 0.85 GAA (0.44) MAPTCYP3A4CYP2C9CYP2C19MEN1
SCHEMBL6386592 0.84 MAPT (0.43) MAPTCYP2C9CYP2C19MEN1KMT2A
SCHEMBL6427395 0.83 KMT2A (0.40) MAPTCYP3A4MEN1KMT2AALDH1A1
SCHEMBL6427929 0.79 MEN1 (0.39) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL6426785 0.77 MAPT (0.38) MAPTCYP3A4CYP2C9CYP2C19MEN1
SCHEMBL6428317 0.77 PKM (0.40) MAPTMEN1KMT2AALDH1A1USP2
SCHEMBL6425910 0.75 PKM (0.46) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL6428237 0.74 PKM (0.48) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL6393714 0.74 EPHX2 (0.44) MAPTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 MAPT 3607/4885CYP3A4 78/4885CYP2C9 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.